Dysregulated JAK2 expression by TrkC promotes metastasis potential, and EMT program of metastatic breast cancer

Min Soo Kim, Joon Jeong, Jeongbeob Seo, Hae Suk Kim, Seong Jin Kim, Wook Jin

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Metastatic breast cancers are aggressive tumors associated with high levels of epithelial-mesenchymal transition (EMT) markers, activation of IL6/JAK2/STAT3 and PI3K/AKT pathways for cell growth, mobility, invasion, metastasis, and CSC status. We identified a new molecular and functional network present in metastasis that regulates and coordinates with TrkC. Inhibition of SOCS3-mediated JAK2 degradation by TrkC increases total JAK2/STAT3 expression, and then leads to upregulation of Twist-1 through activation of JAK2/STAT3 cascade. Also, TrkC increases secretion and expression of IL-6, suggesting that this autocrine loop generated by TrkC maintains the mesenchymal state by continued activation of the JAK2/STAT3 cascade and upregulation of Twist expression. Moreover, TrkC interacts with the c-Src/Jak2 complex, which increases Twist-1 and Twist-2 levels via regulation of JAK2/STAT3 activation and JAK2/STAT3 expression. Furthermore, TrkC enhances metastatic potential of breast cancer via induction of EMT by upregulating Twist-1 and Twist-2. Additionally, TrkC significantly enhances the ability of breast cancer cells to form pulmonary metastases and primary tumor formation. Unexpectedly, we found that TrkC expression and clinical breast tumor pathological phenotypes show significant correlation. These findings suggest that TrkC plays a central role in tumorigenicity, metastasis, and self-renewal traits of metastatic breast cancer.

Original languageEnglish
Article number33899
JournalScientific reports
Volume6
DOIs
Publication statusPublished - 2016 Sep 22

Fingerprint

Epithelial-Mesenchymal Transition
Breast Neoplasms
Neoplasm Metastasis
Interleukin-6
Up-Regulation
Phosphatidylinositol 3-Kinases
Neoplasms
Phenotype
Lung
Growth

All Science Journal Classification (ASJC) codes

  • General

Cite this

Kim, Min Soo ; Jeong, Joon ; Seo, Jeongbeob ; Kim, Hae Suk ; Kim, Seong Jin ; Jin, Wook. / Dysregulated JAK2 expression by TrkC promotes metastasis potential, and EMT program of metastatic breast cancer. In: Scientific reports. 2016 ; Vol. 6.
@article{93e16da6ec684d4eaf06b29af5a8894e,
title = "Dysregulated JAK2 expression by TrkC promotes metastasis potential, and EMT program of metastatic breast cancer",
abstract = "Metastatic breast cancers are aggressive tumors associated with high levels of epithelial-mesenchymal transition (EMT) markers, activation of IL6/JAK2/STAT3 and PI3K/AKT pathways for cell growth, mobility, invasion, metastasis, and CSC status. We identified a new molecular and functional network present in metastasis that regulates and coordinates with TrkC. Inhibition of SOCS3-mediated JAK2 degradation by TrkC increases total JAK2/STAT3 expression, and then leads to upregulation of Twist-1 through activation of JAK2/STAT3 cascade. Also, TrkC increases secretion and expression of IL-6, suggesting that this autocrine loop generated by TrkC maintains the mesenchymal state by continued activation of the JAK2/STAT3 cascade and upregulation of Twist expression. Moreover, TrkC interacts with the c-Src/Jak2 complex, which increases Twist-1 and Twist-2 levels via regulation of JAK2/STAT3 activation and JAK2/STAT3 expression. Furthermore, TrkC enhances metastatic potential of breast cancer via induction of EMT by upregulating Twist-1 and Twist-2. Additionally, TrkC significantly enhances the ability of breast cancer cells to form pulmonary metastases and primary tumor formation. Unexpectedly, we found that TrkC expression and clinical breast tumor pathological phenotypes show significant correlation. These findings suggest that TrkC plays a central role in tumorigenicity, metastasis, and self-renewal traits of metastatic breast cancer.",
author = "Kim, {Min Soo} and Joon Jeong and Jeongbeob Seo and Kim, {Hae Suk} and Kim, {Seong Jin} and Wook Jin",
year = "2016",
month = "9",
day = "22",
doi = "10.1038/srep33899",
language = "English",
volume = "6",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",

}

Dysregulated JAK2 expression by TrkC promotes metastasis potential, and EMT program of metastatic breast cancer. / Kim, Min Soo; Jeong, Joon; Seo, Jeongbeob; Kim, Hae Suk; Kim, Seong Jin; Jin, Wook.

In: Scientific reports, Vol. 6, 33899, 22.09.2016.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Dysregulated JAK2 expression by TrkC promotes metastasis potential, and EMT program of metastatic breast cancer

AU - Kim, Min Soo

AU - Jeong, Joon

AU - Seo, Jeongbeob

AU - Kim, Hae Suk

AU - Kim, Seong Jin

AU - Jin, Wook

PY - 2016/9/22

Y1 - 2016/9/22

N2 - Metastatic breast cancers are aggressive tumors associated with high levels of epithelial-mesenchymal transition (EMT) markers, activation of IL6/JAK2/STAT3 and PI3K/AKT pathways for cell growth, mobility, invasion, metastasis, and CSC status. We identified a new molecular and functional network present in metastasis that regulates and coordinates with TrkC. Inhibition of SOCS3-mediated JAK2 degradation by TrkC increases total JAK2/STAT3 expression, and then leads to upregulation of Twist-1 through activation of JAK2/STAT3 cascade. Also, TrkC increases secretion and expression of IL-6, suggesting that this autocrine loop generated by TrkC maintains the mesenchymal state by continued activation of the JAK2/STAT3 cascade and upregulation of Twist expression. Moreover, TrkC interacts with the c-Src/Jak2 complex, which increases Twist-1 and Twist-2 levels via regulation of JAK2/STAT3 activation and JAK2/STAT3 expression. Furthermore, TrkC enhances metastatic potential of breast cancer via induction of EMT by upregulating Twist-1 and Twist-2. Additionally, TrkC significantly enhances the ability of breast cancer cells to form pulmonary metastases and primary tumor formation. Unexpectedly, we found that TrkC expression and clinical breast tumor pathological phenotypes show significant correlation. These findings suggest that TrkC plays a central role in tumorigenicity, metastasis, and self-renewal traits of metastatic breast cancer.

AB - Metastatic breast cancers are aggressive tumors associated with high levels of epithelial-mesenchymal transition (EMT) markers, activation of IL6/JAK2/STAT3 and PI3K/AKT pathways for cell growth, mobility, invasion, metastasis, and CSC status. We identified a new molecular and functional network present in metastasis that regulates and coordinates with TrkC. Inhibition of SOCS3-mediated JAK2 degradation by TrkC increases total JAK2/STAT3 expression, and then leads to upregulation of Twist-1 through activation of JAK2/STAT3 cascade. Also, TrkC increases secretion and expression of IL-6, suggesting that this autocrine loop generated by TrkC maintains the mesenchymal state by continued activation of the JAK2/STAT3 cascade and upregulation of Twist expression. Moreover, TrkC interacts with the c-Src/Jak2 complex, which increases Twist-1 and Twist-2 levels via regulation of JAK2/STAT3 activation and JAK2/STAT3 expression. Furthermore, TrkC enhances metastatic potential of breast cancer via induction of EMT by upregulating Twist-1 and Twist-2. Additionally, TrkC significantly enhances the ability of breast cancer cells to form pulmonary metastases and primary tumor formation. Unexpectedly, we found that TrkC expression and clinical breast tumor pathological phenotypes show significant correlation. These findings suggest that TrkC plays a central role in tumorigenicity, metastasis, and self-renewal traits of metastatic breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=84988666970&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84988666970&partnerID=8YFLogxK

U2 - 10.1038/srep33899

DO - 10.1038/srep33899

M3 - Article

AN - SCOPUS:84988666970

VL - 6

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

M1 - 33899

ER -